Drugs.com Releases Q2 Sales for Top 100 U.S. Prescription Drugs: Humira Climbs into Top 5 and Posts Double-Digit Growth

Drugs.com Releases Q2 Sales for Top 100 U.S. Prescription Drugs: Humira Climbs
                   into Top 5 and Posts Double-Digit Growth

PR Newswire

NEW YORK, Aug. 14, 2013

NEW YORK, Aug. 14, 2013 /PRNewswire/ --Drugs.com, the leading online clinical
drug resource, today released second quarter 2013 U.S. prescription sales data
for the top 100 drugs. Since Q2 2012, Otuska's antipsychotic Abilify and
AstraZeneca's acid reducer Nexium have held either the number one or two spot
in top dollar sales. This quarter, both agents continue to maintain their
stronghold; each posts close to $1.5 billion in sales. Humira, AbbVie's key
tumor necrosis factor (TNF) blocker, climbs three notches and sees a
double-digit gain for the quarter.

(Photo: http://photos.prnewswire.com/prnh/20130814/PH63256-a )
(Photo: http://photos.prnewswire.com/prnh/20130814/PH63256-b )

Top Five Drugs by Sales, Q2 2013

                       % Change (previous
Drug Name Sales ($000)
Abilify   $1,597,913   +4.70%
Nexium    $1,454,048   -0.34%
Humira    $1,341,759   +10.22%
Cymbalta  $1,338,912   +3.24%
Crestor   $1,290,913   -0.37%

The move of Humira into the top five shifts both Eli Lilly's Cymbalta, and
AstraZeneca's Crestor down one position. Cymbalta, which reaped over $4.4
billion in 2012 U.S. sales, goes off patent this December.

Top Five Sales Gains, Q2 2013

                        % Change (previous
Drug Name   Gain ($000)
Humira      $124,407    +10.22%
doxycycline $89,309     +46.22%
Enbrel      $72,681     +6.76%
Abilify     $71,685     +4.70%
Epogen      $47,324     +9.40%

Not only does Humira re-enter the top five drugs by sales, it also comes in at
the number one spot in terms of sales growth. Enbrel, another TNF blocker,
returns to positive growth after a slight drop in Q1. Abilify and Epogen round
out the fourth and fifth spots in quarterly sales gains.

"The significant impact of TNF blockers on autoimmune disease activity is not
only reflected in their varied indications such as rheumatoid arthritis,
psoriasis and Crohn's disease, but also in their steady sales growth," said
Philip Thornton, CEO of Drugs.com. "Since the second quarter of 2012, Humira,
Enbrel, and Remicade have all placed in the top ten with revenues in the $1
billion range."

Top Five Sales Losses, Q2 2013

                          % Change (previous
Drug Name     Loss ($000)
Avonex Pen    -$154,859   -45.78%
Suboxone      -$78,819    -18.95%
Advair Diskus -$35,740    -2.80%
Avonex        -$32,162    -9.51%
modafinil     -$31,418    -14.37%

Newer oral multiple sclerosis (MS) agents such as Novartis'Gilenya may now be
impacting the use of injectable interferon such as Biogen Idec's Avonex, which
loses significant growth this quarter. However, the news may not be all bad --
Biogen Idec also manufactures Tecfidera, the newest oral MS drug -- predicted
to draw in over $3.5 billion in annual sales by 2017. Modafinil lost over 17
percent in sales gains in Q1 2013, and continues to slide this quarter.

Reckitt Benckiser's Suboxone for opiate dependence, now available only in the
oral dissolvable film, drops close to $79 million. The sublingual tablet
formulation of Suboxone, discontinued in March, can now be replaced with the
generic version approved in February.

Detailed data on the top 100 drugs can be accessed at:

About Drugs.com
Drugs.com is the leading online drug information resource with over nine
million unique visitors per month (ComScore, June 2013). Providing free,
independent, peer-reviewed, and up-to-date information at both consumer and
professional levels, Drugs.com empowers patients and caregivers to take charge
of their health and be more informed than ever before. The site includes many
interactive tools and mobile apps to assist consumers, healthcare
professionals and researchers, such as personal medication records, a drug
interaction checker, pill identification wizard, symptom checker, pharma sales
statistics and more.

For more information, visit: http://www.drugs.com/

Media Inquiries:
Drugs.com Press Officer
(718) 395 2473

Read more news from Drugs.com.

SOURCE Drugs.com

Website: http://www.drugs.com
Contact: Paul Wager
Press spacebar to pause and continue. Press esc to stop.